Clozapine in Treatment-Resistant Schizophrenia: Bridging Underuse, Safety Monitoring, and Practical Management

Clozapine is the antipsychotic that guidelines recommend for treatment-resistant schizophrenia, yet it is started late, or not at all, for many eligible patients. This narrative review asks how strong the evidence for its benefit is, why it remains underused, and how its risks can be monitored and managed. We searched PubMed in November 2026 and summarized randomized trials, network meta-analyses, nationwide cohorts, barriers to prescribing worldwide and in the Arab world, and the monitoring of neutropenia, myocarditis, gastrointestinal hypomotility, pneumonia, seizures, sialorrhea and metabolic effects. The evidence for benefit is not uniform. Registry cohorts generally favor clozapine for rehospitalization and mortality, whereas a recent individual-patient-data meta-analysis of blinded trials found no evidence of superior efficacy over other second-generation antipsychotics, with very low confidence in the evidence; two network meta-analyses disagree on the size of the advantage but still call clozapine the gold standard. Monitoring recommendations are changing: a Delphi consensus and a European task force propose lower neutrophil thresholds and less frequent blood counts after the first one to two years, and a 2025 European revision adopted neutrophil-only counts and a lower discontinuation threshold. Attention has moved to myocarditis, constipation, ileus and pneumonia. Saudi studies report high serum concentrations and frequent laboratory abnormalities but are small and retrospective or cross-sectional. We close with a practical framework for initiation, titration, monitoring and augmentation, with each statement labeled by its type of evidence.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-22
DOI
https://doi.org/10.5281/zenodo.24430889
Primary Topic
Schizophrenia research and treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clozapine in Treatment-Resistant Schizophrenia: Bridging Underuse, Safety Monitoring, and Practical Management

Salman Mashary Alharbi, Yusuf Mohammad Alkahtani
Zenodo (CERN European Organization for Nuclear Research)
Schizophrenia research and treatment
preprint

Clozapine in Treatment-Resistant Schizophrenia: Bridging Underuse, Safety Monitoring, and Practical Management

Salman Mashary Alharbi, Yusuf Mohammad Alkahtani
preprint en

Abstract

Clozapine is the antipsychotic that guidelines recommend for treatment-resistant schizophrenia, yet it is started late, or not at all, for many eligible patients. This narrative review asks how strong the evidence for its benefit is, why it remains underused, and how its risks can be monitored and managed. We searched PubMed in November 2026 and summarized randomized trials, network meta-analyses, nationwide cohorts, barriers to prescribing worldwide and in the Arab world, and the monitoring of neutropenia, myocarditis, gastrointestinal hypomotility, pneumonia, seizures, sialorrhea and metabolic effects. The evidence for benefit is not uniform. Registry cohorts generally favor clozapine for rehospitalization and mortality, whereas a recent individual-patient-data meta-analysis of blinded trials found no evidence of superior efficacy over other second-generation antipsychotics, with very low confidence in the evidence; two network meta-analyses disagree on the size of the advantage but still call clozapine the gold standard. Monitoring recommendations are changing: a Delphi consensus and a European task force propose lower neutrophil thresholds and less frequent blood counts after the first one to two years, and a 2025 European revision adopted neutrophil-only counts and a lower discontinuation threshold. Attention has moved to myocarditis, constipation, ileus and pneumonia. Saudi studies report high serum concentrations and frequent laboratory abnormalities but are small and retrospective or cross-sectional. We close with a practical framework for initiation, titration, monitoring and augmentation, with each statement labeled by its type of evidence.

Zenodo (CERN European Organization for Nuclear Research)
King Saud University (SA)
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon